Antiplatelet Drug Resistances and Ischemic Events

Antiplatelet Drug Resistances and Ischemic Events

The ADRIE study is an observational study on the clinical relevance of platelet reactivity in aspirin and clopidogrel treated cardiovascular patients.

The ADRIE study is an observational study on the clinical relevance of platelet reactivity in aspirin and clopidogrel treated cardiovascular patients.

Main objective:

• to determine if platelet reactivity, assessed by specific and non-specific tests, is predictive of ischemic events during the 3-year follow-up.

Secondary objectives:

• primary outcome in each pre-specified sub-group : patients with coronary artery disease, ischemic stroke or peripheral arterial disease as main qualifying disease at entry,
• to determine if platelet reactivity, assessed by specific and non-specific tests, is predictive of bleeding events during the 3-year follow-up,
• to investigate potential determinants of platelet reactivity at entry in the study

Inclusion Criteria:

• Documented symptomatic ischemic atherothrombotic disease treated by aspirin, clopidogrel or both.

Exclusion Criteria:

• Known platelet disorder
• Chronic treatment by antiplatelet drugs other than aspirin or clopidogrel.
• Chronic anticoagulant treatment
• Chronic non steroid anti inflammatory drug treatment
• Active cancer
• Ongoing aspirin or clopidogrel treatment taken for more than 5 years prior to inclusion